-
Techniques in Vascular and... Sep 2023Advancements in minimally invasive technology, coupled with imaging breakthroughs, have empowered the field of interventional radiology to achieve unparalleled precision... (Review)
Review
Advancements in minimally invasive technology, coupled with imaging breakthroughs, have empowered the field of interventional radiology to achieve unparalleled precision in image-guided diagnosis and treatment while simultaneously reducing periprocedural morbidity. Molecular imaging, which provides valuable physiological and metabolic information alongside anatomical localization, can expand the capabilities of image-guided interventions. Among various molecular imaging techniques, positron emission tomography (PET) stands out for its superior spatial resolution and ability to acquire quantitative data. PET has emerged as a crucial tool for oncologic imaging and plays a pivotal role in both staging and the assessment of treatment responses. Typically used in combination with computed tomography (CT) (PET/CT) and occasionally with magnetic resonance imaging MRI (PET/MRI), PET as a hybrid imaging approach offers enhanced insights into disease progression and response. In recent years, PET has also found its way into image-guided interventions, especially within the rapidly expanding field of interventional oncology. This review aims to explore the current and evolving role of metabolic imaging, specifically PET, in interventional oncology. By delving into the unique advantages and applications of PET in guiding oncological interventions and assessing response, we seek to highlight the increasing significance of this modality in the realm of interventional radiology.
Topics: Humans; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Tomography, X-Ray Computed; Multimodal Imaging; Magnetic Resonance Imaging
PubMed: 38071029
DOI: 10.1016/j.tvir.2023.100916 -
Der Radiologe May 2020Positron-emission tomography/computed tomography (PET/CT) and positron-emission tomography/magnetic resonance imaging (PET/MRI) are hybrid medical imaging techniques... (Review)
Review
BACKGROUND
Positron-emission tomography/computed tomography (PET/CT) and positron-emission tomography/magnetic resonance imaging (PET/MRI) are hybrid medical imaging techniques that are becoming increasingly important in the diagnostic workup of cancer. Correct definition and interpretation of results are key challenges for both radiologists/specialists in nuclear medicine as well as for the treating clinician. Strong interdisciplinary communication is prerequisite to solve the upcoming complexity of retrieved information generated by hybrid imaging.
OBJECTIVES
Different indications for hybrid medical imaging and review of current theranostic principles from the perspective of clinicians/clinical oncologists.
MATERIALS AND METHODS
The GBA guidelines and recommendations retrieved from the corresponding German S3 guidelines for the use of PET imaging are summarized, followed by a review of innovative clinical trials that promote PET-based therapeutic strategies and radioligand therapies.
RESULTS
Next generation PET/CT and PET/MRI imaging are being increasingly used for diagnostic purposes and follow-up staging in malignant tumors. Radioligand therapy may have the potential to be a further cornerstone in personalized antitumor therapy.
CONCLUSIONS
Careful implementation of hybrid medical imaging can clearly improve the quality of the diagnosis in cancer patients and even increase the quality of care for cancer patients. Close interdisciplinary collaboration is essential to optimize therapeutic strategies for each patient.
Topics: Humans; Interprofessional Relations; Multimodal Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiologists
PubMed: 32052117
DOI: 10.1007/s00117-020-00653-x -
Biochemical Society Transactions Aug 2015The 18-kDA translocator protein (TSPO) is consistently elevated in activated microglia of the central nervous system (CNS) in response to a variety of insults as well as... (Review)
Review
The 18-kDA translocator protein (TSPO) is consistently elevated in activated microglia of the central nervous system (CNS) in response to a variety of insults as well as neurodegenerative and psychiatric conditions. It is therefore a target of interest for molecular strategies aimed at imaging neuroinflammation in vivo. For more than 20 years, positron emission tomography (PET) has allowed the imaging of TSPO density in brain using [(11)C]-(R)-PK11195, a radiolabelled-specific antagonist of the TSPO that has demonstrated microglial activation in a large number pathological cohorts. The significant clinical interest in brain immunity as a primary or comorbid factor in illness has sparked great interest in the TSPO as a biomarker and a surprising number of second generation TSPO radiotracers have been developed aimed at improving the quality of TSPO imaging through novel radioligands with higher affinity. However, such major investment has not yet resulted in the expected improvement in image quality. We here review the main methodological aspects of TSPO PET imaging with particular attention to TSPO genetics, cellular heterogeneity of TSPO in brain tissue and TSPO distribution in blood and plasma that need to be considered in the quantification of PET data to avoid spurious results as well as ineffective development and use of these radiotracers.
Topics: Humans; Isoquinolines; Microglia; Positron-Emission Tomography; Receptors, GABA
PubMed: 26551697
DOI: 10.1042/BST20150058 -
Rheumatology (Oxford, England) Apr 2022
Topics: Arthritis, Rheumatoid; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Tumor Necrosis Factor Inhibitors
PubMed: 34919664
DOI: 10.1093/rheumatology/keab932 -
PET Clinics Oct 2023Many novel PET radiotracers have demonstrated potential use in breast cancer. Although not currently approved for clinical use in the breast cancer population, these... (Review)
Review
Many novel PET radiotracers have demonstrated potential use in breast cancer. Although not currently approved for clinical use in the breast cancer population, these innovative imaging agents may one day play a role in the diagnosis, staging, management, and even treatment of breast cancer.
Topics: Humans; Female; Breast Neoplasms; Radiopharmaceuticals; Positron-Emission Tomography; Positron Emission Tomography Computed Tomography
PubMed: 37369615
DOI: 10.1016/j.cpet.2023.05.001 -
Methods in Molecular Biology (Clifton,... 2024Positron emission tomography (PET) is one of the most sensitive whole-body molecular imaging techniques available in the clinic, able to detect picomolar levels of...
Positron emission tomography (PET) is one of the most sensitive whole-body molecular imaging techniques available in the clinic, able to detect picomolar levels of probe. As such, it was recently demonstrated that PET could also be used to track single radiolabeled cells in small animals. In this protocol, we present detailed procedures for radiolabeling cells using mesoporous silica nanoparticles (MSNs) and for tracking these cells in real time using in vivo PET. This includes static imaging of single cells as well as dynamic tracking of moving cells directly from the list-mode data. The protocol provides detailed instructions and examples for each step.
Topics: Animals; Positron-Emission Tomography; Nanoparticles; Whole Body Imaging
PubMed: 38006505
DOI: 10.1007/978-1-0716-3499-8_19 -
Zeitschrift Fur Medizinische Physik Feb 2023
Topics: Precision Medicine; Electrons; Positron-Emission Tomography; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Fluorodeoxyglucose F18
PubMed: 36710155
DOI: 10.1016/j.zemedi.2023.01.006 -
PET Clinics Jul 2022Molecular imaging with PET-computerized tomography (PET-CT) plays an important role in oncology. There is current and evolving evidence supporting the use of... (Review)
Review
Molecular imaging with PET-computerized tomography (PET-CT) plays an important role in oncology. There is current and evolving evidence supporting the use of fluorodeoxyglucose (FDG) and non-FDG tracers in assessment patients with hepatobiliary and pancreatic cancers in various clinical scenarios. In this chapter, we discuss the advantages and limitations of FDG and non-FDG PET-CT in the management of patients with hepatobiliary and pancreatic cancers.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals
PubMed: 35717098
DOI: 10.1016/j.cpet.2022.03.007 -
Methods in Molecular Biology (Clifton,... 2024Positron emission tomography (PET) is a highly sensitive molecular imaging technique that uses radioactive tracers to map molecular and metabolic processes in living...
Positron emission tomography (PET) is a highly sensitive molecular imaging technique that uses radioactive tracers to map molecular and metabolic processes in living animals. PET can be performed as a stand-alone modality but is often combined with CT to provide for objective anatomical localization of PET signals in a multimodality approach. In order to outline the general approach to evaluating four mice simultaneously by dynamic PET imaging, the use of the aldehyde-targeted radiotracer [F]NABF in mouse models of hepatotoxicity will be described. Indeed the production of aldehydes is upregulated in a wide range of disease and injury, making them a suitable biomarker for PET imaging of numerous pathologies.
Topics: Mice; Animals; Positron Emission Tomography Computed Tomography; Workflow; Positron-Emission Tomography; Multimodal Imaging; Radioactive Tracers
PubMed: 38006497
DOI: 10.1007/978-1-0716-3499-8_11 -
PET Clinics Apr 2022Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) has an integral role in modern radiotherapy planning for most patients with head and neck... (Review)
Review
Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) has an integral role in modern radiotherapy planning for most patients with head and neck malignancies. Fluorine-18-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) should guide standard target delineation and has emerging roles in dose and volume modification for escalation/de-escalation and adaptive radiotherapy. This article discusses the integration of PET/CT into radiotherapy planning.
Topics: Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed
PubMed: 35256302
DOI: 10.1016/j.cpet.2021.12.007